Prolonged survival associated with anti-HER2 therapy: case report




Introduction: The advent of targeted therapy for human epidermal growth factor receptor 2 (HER-2), introduced by trastuzumab, represented a significant advancement in the treatment of breast cancer, impacting the survival of patients who overexpress this protein. Long-term survival (> 5 years) remains rare according to the literature, with an average of 25%. Case Report: This is a single-case observational report of a patient with extended survival in HER-2+ breast cancer treatment with trastuzumab combined with other medications. Clinical, pathological, treatment history, and survival data were retrospectively collected from the medical records. Patient, female, 37 years old, premenopausal, without associated comorbidities, physically active, no history of smoking or alcohol consumption, diagnosed in March 2015. She underwent intravenous chemotherapy for palliative purposes, achieving a maximal response. Trastuzumab was continued, combined with anastrozole, and she currently presents stable disease and extended survival (> 5 years). Targeted therapies significantly improve survival outcomes for HER2+ breast cancer patients. Recent studies demonstrate that clinical outcomes are better for triple-positive patients (ER, PR, and HER-2 positive), highlighting how this therapy has altered the natural course of the disease. There is evidence that the continuation of targeted therapy after disease progression results in clinical benefit, however, there is no consensus on the duration of treatment. Conclusion: This case, of a young patient diagnosed with HER2+ metastatic breast cancer, with long-term survival exceeding that described in the literature, demonstrates that the extended use of targeted therapy with trastuzumab, in combination with various chemotherapy and hormone-therapies regimens, can lead to the prolongation and improvement of the quality of life for patients whose prognosis at diagnosis was discouraging. This fact may assist in future decision-making regarding the use of targeted therapy after disease progression, filling this gap in knowledge.


Download data is not yet available.


Ferlay J, Colombet M, Soerjomataram I et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods- Ferlay- 2019- International Journal of Cancer- Wiley Online Library. 2022.

INCA, Intituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2023: incidência de câncer no Brasil. 2022. Disponível em: INCA estima 704 mil casos de câncer por ano no Brasil até 2025 — Português (Brasil) ( acesso em: 29/12/2022 às 17:13h.

Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nature reviews. Disease primers. 2019; 5(1).

Fabi A, Malaguti P, Vari S et al. First-line therapy in HER2 po- sitive metastatic breast cancer: is the mosaic fully comple- ted or are we missing additional pieces? Journal of experimental & clinical cancer research : CR, 2018;35. https://doi. org/10.1186/s13046-016-0380-5

Kelmer T F, Silva M JS, & Retto M P F. Estudos clínicos ran- domizados para registro de biossimilares trastuzumabe: uma revisão de escopo, Brasil, 2020. Vigilância sanitária em debate: sociedade, ciência e tecnologia. 2020; 9(4), 86-93.

Kast K, Schoffer O, Link T et al. Trastuzumab and survival of patients with metastatic breast cancer. Archives of gyneco- logy and obstetrics. 2017; 296(2).

Lobbezoo D, Kampen R V, Voogd A et al. Prognosis of metasta- tic breast cancer subtypes: the hormone receptor/HER2-po- sitive subtype is associated with the most favorable outcome. Breast cancer research and treatment. 2013; 141(3). https://

Arciénega II, Imech P, Fink D et al. Prolonged complete re- mission of metastatic HER2-positive breast cancer after con- tinuous trastuzumab treatment: a case report and review of the literature. Targeted oncology. 2015;10(2). https://doi. org/10.1007/s11523-014-0350-9

Yeo B, Kotsori K, Mohammed K, Walsh G, & Smith I. Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast (Edinburgh, Scotland). 2015; 24(6).

Cantini L, Pistelli M, Savini A, et al. Long-responders to anti-HER2 therapies: A case report and review of the literature. MOLECULAR AND CLINICAL ONCOLOGY. 2018;8. 147-152,.

Moilanen T, Mustanoja S, Karihtala P, & Koivunen J. Retros- pective analysis of HER2 therapy interruption in patients res- ponding to the treatment in metastatic HER2+ breast cancer. ESMO open. 2017; 2(3). pen-2017-000202

Viel E, Arbion F, Barbe C, & Bougnoux P. Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metasta- ses: the prospect of disappearance of an incurable disease. BMC cancer. 2014; 14.

Waddell T, Kotsori A, Constantinidou A et al. Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. British journal of cancer. 2011;104(11).

Minckwitz GV, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European journal of cancer (Oxford, England : 1990). 2011; 47(15).

Krasniqi E, Barchiesi G, Mazzotta M et al. Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. Medicine. 2020; 99(31).



How to Cite

PORTELLA PR, FERREIRA LA, FÁVERO-RETTO MP. Prolonged survival associated with anti-HER2 therapy: case report. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Jan.8 [cited 2024Feb.22];14(4):1011. Available from: